Joohyuk Sohn

27.4k total citations · 10 hit papers
303 papers, 10.9k citations indexed

About

Joohyuk Sohn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joohyuk Sohn has authored 303 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Oncology, 163 papers in Pulmonary and Respiratory Medicine and 89 papers in Cancer Research. Recurrent topics in Joohyuk Sohn's work include Advanced Breast Cancer Therapies (126 papers), Cancer Treatment and Pharmacology (92 papers) and HER2/EGFR in Cancer Research (91 papers). Joohyuk Sohn is often cited by papers focused on Advanced Breast Cancer Therapies (126 papers), Cancer Treatment and Pharmacology (92 papers) and HER2/EGFR in Cancer Research (91 papers). Joohyuk Sohn collaborates with scholars based in South Korea, United States and Spain. Joohyuk Sohn's co-authors include Susana Barriga, Masakazu Toi, Martin Frenzel, Seung Il Kim, Xavier Pivot, Nawel Bourayou, Nadia Harbeck, Norikazu Masuda, Patrick Neven and George W. Sledge and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Joohyuk Sohn

292 papers receiving 10.7k citations

Hit Papers

MONARCH 3: Abemaciclib As Initial Therapy for ... 2010 2026 2015 2020 2017 2017 2020 2010 2019 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
    2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
  2. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
    2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
  3. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
    2020 718 citations Carlos H. Barrios, Kyung Hae Jung et al. profile →
  4. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2010 700 citations Luc Dirix, Javier Cortés et al. Journal of Clinical Oncology profile →
  5. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
    2019 591 citations Seock‐Ah Im, Yen‐Shen Lu et al. New England Journal of Medicine profile →
  6. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
    2019 590 citations George W. Sledge, Masakazu Toi et al. profile →
  7. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
    2020 279 citations Y.H. Park, Eva Muñoz‐Couselo et al. Annals of Oncology profile →
  8. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
    2021 160 citations Joohyuk Sohn, Kan Yonemori et al. profile →
  9. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
    2024 144 citations Aditya Bardia, Xichun Hu et al. New England Journal of Medicine profile →
  10. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).
    2024 52 citations Giuseppe Curigliano, Rebecca Dent et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joohyuk Sohn South Korea 44 7.9k 5.6k 3.3k 1.8k 1.3k 303 10.9k
Denise A. Yardley United States 50 9.8k 1.2× 4.5k 0.8× 3.3k 1.0× 2.8k 1.5× 917 0.7× 279 12.8k
Joyce O’Shaughnessy United States 40 7.0k 0.9× 2.8k 0.5× 3.1k 0.9× 2.1k 1.2× 524 0.4× 240 9.6k
Norikazu Masuda Japan 45 9.9k 1.3× 7.0k 1.3× 4.4k 1.3× 3.0k 1.6× 1.6k 1.3× 389 14.0k
Sara A. Hurvitz United States 53 8.2k 1.0× 4.2k 0.8× 2.6k 0.8× 3.2k 1.8× 1.0k 0.8× 375 11.0k
Sara M. Tolaney United States 54 11.6k 1.5× 5.3k 1.0× 3.7k 1.1× 2.8k 1.5× 1.1k 0.9× 502 14.8k
Vivek Subbiah United States 54 6.0k 0.8× 4.6k 0.8× 3.1k 1.0× 3.7k 2.0× 637 0.5× 599 12.2k
Igor Bondarenko United States 54 13.3k 1.7× 9.0k 1.6× 3.6k 1.1× 3.3k 1.8× 1.3k 1.0× 317 17.7k
Kimberly Blackwell United States 50 6.0k 0.8× 2.4k 0.4× 1.9k 0.6× 2.1k 1.2× 790 0.6× 138 9.2k
Jean‐Yves Pierga France 59 8.0k 1.0× 3.5k 0.6× 6.3k 1.9× 2.3k 1.3× 651 0.5× 331 12.0k
Anthony Gonçalvès France 45 6.2k 0.8× 3.0k 0.5× 2.3k 0.7× 2.8k 1.5× 572 0.4× 318 9.5k

Countries citing papers authored by Joohyuk Sohn

Since Specialization
Citations

This map shows the geographic impact of Joohyuk Sohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joohyuk Sohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joohyuk Sohn more than expected).

Fields of papers citing papers by Joohyuk Sohn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joohyuk Sohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joohyuk Sohn. The network helps show where Joohyuk Sohn may publish in the future.

Co-authorship network of co-authors of Joohyuk Sohn

This figure shows the co-authorship network connecting the top 25 collaborators of Joohyuk Sohn. A scholar is included among the top collaborators of Joohyuk Sohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joohyuk Sohn. Joohyuk Sohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Park, Ji Won, et al.. (2025). Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response. Antioxidants and Redox Signaling. 43(4-6). 288–307. 6 indexed citations
4.
Xu, Binghe, Shusen Wang, Min Yan, et al.. (2024). Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nature Medicine. 30(12). 3709–3716. 14 indexed citations
5.
Bardia, Aditya, Xichun Hu, Rebecca Dent, et al.. (2024). Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine. 391(22). 2110–2122. 144 indexed citations breakdown →
6.
Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations
7.
Lee, Dae‐Won, Kyung Hae Jung, Kyung-Hun Lee, et al.. (2023). Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. European Journal of Cancer. 197. 113456–113456. 1 indexed citations
8.
Saura, Cristina, Shanu Modi, Ian E. Krop, et al.. (2023). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Annals of Oncology. 35(3). 302–307. 50 indexed citations
9.
Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2021). MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer. Clinical Cancer Research. 27(21). 5801–5809. 7 indexed citations
10.
11.
Rugo, Hope S., Aditya Bardia, Sara M. Tolaney, et al.. (2020). TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer. Future Oncology. 16(12). 705–715. 89 indexed citations
12.
13.
Jeong, Jae Ho, Jeong Eun Kim, Jin‐Hee Ahn, et al.. (2020). Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. European Journal of Cancer. 144. 341–350. 7 indexed citations
14.
Sharma, Padmanee, Joohyuk Sohn, Sang Joon Shin, et al.. (2019). Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clinical Cancer Research. 26(1). 61–70. 34 indexed citations
15.
Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology. 35(25). 2875–2884. 1103 indexed citations breakdown →
16.
Schmid, Peter, Yeon Hee Park, Eva Muñoz‐Couselo, et al.. (2017). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. Journal of Clinical Oncology. 35(15_suppl). 556–556. 68 indexed citations
17.
Kim, Se Hyun, Kyung Hae Jung, Tae‐Yong Kim, et al.. (2016). Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. Cancer Research and Treatment. 48(4). 1373–1381. 8 indexed citations
18.
19.
Lee, Hye Won, So‐Youn Jung, Youngmee Kwon, et al.. (2012). Metaplastic breast cancer: clinicopathological features and its prognosis. Journal of Clinical Pathology. 65(5). 441–446. 96 indexed citations
20.
Moon, Yong Wha, Seho Park, Joohyuk Sohn, et al.. (2011). Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Journal of Cancer Research and Clinical Oncology. 137(7). 1123–1130. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Denise A. Yardley Breakdown of academic impact, for papers by Joyce O’Shaughnessy Breakdown of academic impact, for papers by Norikazu Masuda Breakdown of academic impact, for papers by Sara A. Hurvitz Breakdown of academic impact, for papers by Sara M. Tolaney Breakdown of academic impact, for papers by Vivek Subbiah Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Kimberly Blackwell Breakdown of academic impact, for papers by Jean‐Yves Pierga Breakdown of academic impact, for papers by Anthony Gonçalvès
Rankless by CCL
2026